Comparative Pharmacology
Head-to-head clinical analysis: OGEN 625 versus STILBESTROL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OGEN 625 versus STILBESTROL.
OGEN .625 vs STILBESTROL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Estrogen replacement therapy; estrogen binds to estrogen receptors, which then translocate to the nucleus and modulate gene transcription, leading to effects such as proliferation of the endometrium and regulation of gonadotropin secretion.
Synthetic nonsteroidal estrogen that acts by binding to estrogen receptors (ERα and ERβ), leading to translocation to the nucleus, modulation of gene transcription, and promotion of estrogenic effects in target tissues.
0.625 mg orally once daily
0.5 to 2 mg orally once daily; or 25 mg intramuscularly once daily for 5 days; for prostate cancer: 1 to 3 mg orally once daily.
None Documented
None Documented
Estrone: 10-24 hours; equilin: 12-18 hours; terminal half-life supports once-daily dosing.
Clinical Note
moderateDiethylstilbestrol + Digoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateDiethylstilbestrol + Digitoxin
"Diethylstilbestrol may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateDiethylstilbestrol + Deslanoside
"Diethylstilbestrol may decrease the cardiotoxic activities of Deslanoside."
Clinical Note
moderateDiethylstilbestrol + Acetyldigitoxin
Terminal elimination half-life is approximately 24-48 hours, with a prolonged phase due to enterohepatic recirculation; requires dosing adjustment in hepatic impairment.
Renal (primarily as glucuronide and sulfate conjugates, ~50-80% of a dose), fecal (~10-20%), with enterohepatic recirculation.
Renal excretion of glucuronide and sulfate conjugates accounts for approximately 60-80% of an administered dose; biliary/fecal excretion accounts for 15-30%; less than 5% is excreted unchanged in urine.
Category C
Category C
Estrogen
Estrogen
"Diethylstilbestrol may decrease the cardiotoxic activities of Acetyldigitoxin."